nodes	percent_of_prediction	percent_of_DWPC	metapath
Metipranolol—Atrial fibrillation—Vandetanib—thyroid cancer	0.0439	0.0439	CcSEcCtD
Metipranolol—Bronchitis—Vandetanib—thyroid cancer	0.0346	0.0346	CcSEcCtD
Metipranolol—Conjunctivitis—Vandetanib—thyroid cancer	0.0312	0.0312	CcSEcCtD
Metipranolol—Epistaxis—Vandetanib—thyroid cancer	0.0303	0.0303	CcSEcCtD
Metipranolol—Bradycardia—Vandetanib—thyroid cancer	0.0293	0.0293	CcSEcCtD
Metipranolol—Visual impairment—Vandetanib—thyroid cancer	0.0278	0.0278	CcSEcCtD
Metipranolol—Lacrimation—Epirubicin—thyroid cancer	0.0243	0.0243	CcSEcCtD
Metipranolol—Vision blurred—Vandetanib—thyroid cancer	0.0236	0.0236	CcSEcCtD
Metipranolol—Lacrimation—Doxorubicin—thyroid cancer	0.0225	0.0225	CcSEcCtD
Metipranolol—Cough—Vandetanib—thyroid cancer	0.0219	0.0219	CcSEcCtD
Metipranolol—Hypertension—Vandetanib—thyroid cancer	0.0216	0.0216	CcSEcCtD
Metipranolol—Acute coronary syndrome—Sorafenib—thyroid cancer	0.0213	0.0213	CcSEcCtD
Metipranolol—Anxiety—Vandetanib—thyroid cancer	0.0213	0.0213	CcSEcCtD
Metipranolol—Myocardial infarction—Sorafenib—thyroid cancer	0.0212	0.0212	CcSEcCtD
Metipranolol—Oedema—Vandetanib—thyroid cancer	0.0205	0.0205	CcSEcCtD
Metipranolol—Epistaxis—Sorafenib—thyroid cancer	0.0204	0.0204	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.0186	0.0186	CcSEcCtD
Metipranolol—Dyspnoea—Vandetanib—thyroid cancer	0.0182	0.0182	CcSEcCtD
Metipranolol—Lacrimation increased—Epirubicin—thyroid cancer	0.0155	0.0155	CcSEcCtD
Metipranolol—Cough—Sorafenib—thyroid cancer	0.0148	0.0148	CcSEcCtD
Metipranolol—Asthenia—Vandetanib—thyroid cancer	0.0147	0.0147	CcSEcCtD
Metipranolol—Hypertension—Sorafenib—thyroid cancer	0.0146	0.0146	CcSEcCtD
Metipranolol—Myalgia—Sorafenib—thyroid cancer	0.0144	0.0144	CcSEcCtD
Metipranolol—Lacrimation increased—Doxorubicin—thyroid cancer	0.0144	0.0144	CcSEcCtD
Metipranolol—Dizziness—Vandetanib—thyroid cancer	0.0135	0.0135	CcSEcCtD
Metipranolol—Rash—Vandetanib—thyroid cancer	0.0129	0.0129	CcSEcCtD
Metipranolol—Dermatitis—Vandetanib—thyroid cancer	0.0129	0.0129	CcSEcCtD
Metipranolol—Headache—Vandetanib—thyroid cancer	0.0128	0.0128	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.0126	0.0126	CcSEcCtD
Metipranolol—Abnormal vision—Epirubicin—thyroid cancer	0.0125	0.0125	CcSEcCtD
Metipranolol—Dyspnoea—Sorafenib—thyroid cancer	0.0123	0.0123	CcSEcCtD
Metipranolol—Nausea—Vandetanib—thyroid cancer	0.0122	0.0122	CcSEcCtD
Metipranolol—Abnormal vision—Doxorubicin—thyroid cancer	0.0115	0.0115	CcSEcCtD
Metipranolol—Hypersensitivity—Sorafenib—thyroid cancer	0.0102	0.0102	CcSEcCtD
Metipranolol—Asthenia—Sorafenib—thyroid cancer	0.0099	0.0099	CcSEcCtD
Metipranolol—Dizziness—Sorafenib—thyroid cancer	0.00913	0.00913	CcSEcCtD
Metipranolol—Angina pectoris—Epirubicin—thyroid cancer	0.00874	0.00874	CcSEcCtD
Metipranolol—Rash—Sorafenib—thyroid cancer	0.0087	0.0087	CcSEcCtD
Metipranolol—Dermatitis—Sorafenib—thyroid cancer	0.00869	0.00869	CcSEcCtD
Metipranolol—Headache—Sorafenib—thyroid cancer	0.00865	0.00865	CcSEcCtD
Metipranolol—Bronchitis—Epirubicin—thyroid cancer	0.00863	0.00863	CcSEcCtD
Metipranolol—Nausea—Sorafenib—thyroid cancer	0.0082	0.0082	CcSEcCtD
Metipranolol—Angina pectoris—Doxorubicin—thyroid cancer	0.00808	0.00808	CcSEcCtD
Metipranolol—Bronchitis—Doxorubicin—thyroid cancer	0.00798	0.00798	CcSEcCtD
Metipranolol—Conjunctivitis—Epirubicin—thyroid cancer	0.00777	0.00777	CcSEcCtD
Metipranolol—Epistaxis—Epirubicin—thyroid cancer	0.00754	0.00754	CcSEcCtD
Metipranolol—Bradycardia—Epirubicin—thyroid cancer	0.00731	0.00731	CcSEcCtD
Metipranolol—Rhinitis—Epirubicin—thyroid cancer	0.0072	0.0072	CcSEcCtD
Metipranolol—Conjunctivitis—Doxorubicin—thyroid cancer	0.00719	0.00719	CcSEcCtD
Metipranolol—Epistaxis—Doxorubicin—thyroid cancer	0.00698	0.00698	CcSEcCtD
Metipranolol—Visual impairment—Epirubicin—thyroid cancer	0.00692	0.00692	CcSEcCtD
Metipranolol—Bradycardia—Doxorubicin—thyroid cancer	0.00676	0.00676	CcSEcCtD
Metipranolol—Rhinitis—Doxorubicin—thyroid cancer	0.00666	0.00666	CcSEcCtD
Metipranolol—Visual impairment—Doxorubicin—thyroid cancer	0.0064	0.0064	CcSEcCtD
Metipranolol—Tension—Epirubicin—thyroid cancer	0.00613	0.00613	CcSEcCtD
Metipranolol—Nervousness—Epirubicin—thyroid cancer	0.00607	0.00607	CcSEcCtD
Metipranolol—Vision blurred—Epirubicin—thyroid cancer	0.00589	0.00589	CcSEcCtD
Metipranolol—Tension—Doxorubicin—thyroid cancer	0.00567	0.00567	CcSEcCtD
Metipranolol—Nervousness—Doxorubicin—thyroid cancer	0.00562	0.00562	CcSEcCtD
Metipranolol—Palpitations—Epirubicin—thyroid cancer	0.00552	0.00552	CcSEcCtD
Metipranolol—Cough—Epirubicin—thyroid cancer	0.00545	0.00545	CcSEcCtD
Metipranolol—Vision blurred—Doxorubicin—thyroid cancer	0.00545	0.00545	CcSEcCtD
Metipranolol—Hypertension—Epirubicin—thyroid cancer	0.0054	0.0054	CcSEcCtD
Metipranolol—Myalgia—Epirubicin—thyroid cancer	0.00532	0.00532	CcSEcCtD
Metipranolol—Anxiety—Epirubicin—thyroid cancer	0.0053	0.0053	CcSEcCtD
Metipranolol—Discomfort—Epirubicin—thyroid cancer	0.00526	0.00526	CcSEcCtD
Metipranolol—Palpitations—Doxorubicin—thyroid cancer	0.00511	0.00511	CcSEcCtD
Metipranolol—Oedema—Epirubicin—thyroid cancer	0.0051	0.0051	CcSEcCtD
Metipranolol—Cough—Doxorubicin—thyroid cancer	0.00505	0.00505	CcSEcCtD
Metipranolol—Hypertension—Doxorubicin—thyroid cancer	0.00499	0.00499	CcSEcCtD
Metipranolol—Myalgia—Doxorubicin—thyroid cancer	0.00492	0.00492	CcSEcCtD
Metipranolol—Anxiety—Doxorubicin—thyroid cancer	0.00491	0.00491	CcSEcCtD
Metipranolol—Discomfort—Doxorubicin—thyroid cancer	0.00486	0.00486	CcSEcCtD
Metipranolol—Oedema—Doxorubicin—thyroid cancer	0.00472	0.00472	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00465	0.00465	CcSEcCtD
Metipranolol—Dyspnoea—Epirubicin—thyroid cancer	0.00455	0.00455	CcSEcCtD
Metipranolol—Somnolence—Epirubicin—thyroid cancer	0.00453	0.00453	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.0043	0.0043	CcSEcCtD
Metipranolol—Dyspnoea—Doxorubicin—thyroid cancer	0.00421	0.00421	CcSEcCtD
Metipranolol—Somnolence—Doxorubicin—thyroid cancer	0.0042	0.0042	CcSEcCtD
Metipranolol—Hypersensitivity—Epirubicin—thyroid cancer	0.00376	0.00376	CcSEcCtD
Metipranolol—Asthenia—Epirubicin—thyroid cancer	0.00366	0.00366	CcSEcCtD
Metipranolol—Hypersensitivity—Doxorubicin—thyroid cancer	0.00348	0.00348	CcSEcCtD
Metipranolol—Asthenia—Doxorubicin—thyroid cancer	0.00339	0.00339	CcSEcCtD
Metipranolol—Dizziness—Epirubicin—thyroid cancer	0.00337	0.00337	CcSEcCtD
Metipranolol—Rash—Epirubicin—thyroid cancer	0.00322	0.00322	CcSEcCtD
Metipranolol—Dermatitis—Epirubicin—thyroid cancer	0.00321	0.00321	CcSEcCtD
Metipranolol—Headache—Epirubicin—thyroid cancer	0.0032	0.0032	CcSEcCtD
Metipranolol—Dizziness—Doxorubicin—thyroid cancer	0.00312	0.00312	CcSEcCtD
Metipranolol—Nausea—Epirubicin—thyroid cancer	0.00303	0.00303	CcSEcCtD
Metipranolol—Rash—Doxorubicin—thyroid cancer	0.00298	0.00298	CcSEcCtD
Metipranolol—Dermatitis—Doxorubicin—thyroid cancer	0.00297	0.00297	CcSEcCtD
Metipranolol—Headache—Doxorubicin—thyroid cancer	0.00296	0.00296	CcSEcCtD
Metipranolol—Nausea—Doxorubicin—thyroid cancer	0.0028	0.0028	CcSEcCtD
